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Abstract. A decision analytical model is presented and analysed to assess the effectiveness
and cost-effectiveness of routine vaccination against varicella and herpes-zoster, or shingles.
These diseases have as common aetiological agent the varicella-zoster virus (VZV). Zoster can
more likely occur in aged people with declining cell-mediated immunity. The general concern
is that universal varicella vaccination might lead to more cases of zoster: with more vaccinated
children exposure of the general population to varicella infectives become smaller and thus a
larger proportion of older people will have weaker immunity to VZV, leading to more cases of
reactivation of zoster. Our compartment model shows that only two possible equilibria exist, one
without varicella and the other one where varicella and zoster both thrive. Threshold quantities
to distinguish these cases are derived. Cost estimates on a possible herd vaccination program
are discussed indicating a possible tradeoff choice.
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1. Introduction
Varicella (chickenpox) and herpes-zoster (also called shingles) have as common aetiological agent the
varicella-zoster virus (VZV). Before a vaccine was developed in 1994, chickenpox was a common contagious
childhood disease that produces itchy blisters but rarely caused serious problems. However, if adults who
did not have the disease as children contract it, it could cause more serious complications.
Shingles is caused by a reactivation of the virus that causes chickenpox. Once one has had chickenpox,
the VZV lies dormant in his/her nerves and can re-emerge as shingles. The transmission of varicella
occurs by coughing and sneezing, which are highly contagious means of spreading the virus, by direct
contact, and by aerosolization of virus from skin lesions, whereas shingles cannot be passed from one
person to another by air. However, the virus that causes shingles, the VZV, can be spread from a person
with active shingles to a person who has never had chickenpox. In such cases, the person exposed to the
virus might develop chickenpox, but they would not develop shingles. The virus is spread through direct
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contact with fluid from the rash blisters, not through sneezing, coughing or casual contact. Shingles,
which is characterized by a rash of blisters, can be very painful but is not life-threatening.
Varicella vaccine can prevent this disease. Implementation of the universal varicella vaccination pro-
gram was followed by a rapid decline in incidence of the disease. The initially recommended one-dose
schedule provided only limited protection. Currently then, two doses of vaccine are recommended for
children, adolescents, and adults. The interval between the first and the second dose may be short, but
it should be at least one month, standard, 3 to 7 years apart, or even longer, depending on varicella
epidemiology [4]. Thus, the decision concerning an optimal vaccination schedule depends greatly on the
local epidemiological situation [18]. Unfortunately, whatever the schedule, the vaccine-induced immunity
wanes. Vaccine efficacy appears to decline with age: from an overall efficacy against herpes-zoster of
64% when vaccinating at 60-69 years to 38% among those over 70 years of age [16], [17]. Wild-type VZV
infections in those who have been previously vaccinated are called ”breakthrough cases”. Individuals who
become infected with VZV after vaccination have a milder case of varicella with fewer lesions, so that
they are generally less infectious than infected individuals who were never vaccinated [19].
The major concern is that universal varicella vaccination might lead to more cases of zoster [10], [24].
Zoster is more likely to occur in people when their cell-mediated immunity declines with age. As the
fraction of vaccinated children increases, exposure of the general population to varicella infectives become
less frequent. Because fewer people infected in childhood are boosted as they age, a larger proportion of
older people will have weaker immunity to VZV, so that zoster may reactivate in more people.
In this paper we use a decision analytical model to assess the effectiveness and cost-effectiveness of
routine vaccination against varicella and zoster. The model is formulated in Section 2 and analysed in
Section 3. The simulations are presented in Section 4. In Section 5 the model is used to estimate the
cost-effectiveness of vaccination against zoster.
2. Model Formulation
We consider a total population N which is subdivided into susceptibles individuals, S, varicella infectious
individuals, I, vaccinated individulas, V , asymptomatics, A and zoster individuals, Z.
A flow diagram is given in Figure 1; and the associated variables and parameters of the model are
described in Table 1.
The model is given by the following dynamical system:
S˙ = Π − βSI − ρS − µS (2.1)
I˙ = βSI + β1V I − γI − µI
V˙ = ρS − β1V I − σV − µV
A˙ = γI + Z − δA− µA
Z˙ = δA+ σV − Z − µZ
The parameters’ meanings are as follows: Π denotes the immigration rate into class S; β is the
transmission coefficient of the varicella infection and represents the number of adequate contacts leading
to new cases per individual per time unit, i.e., the effective contact rate; ρ is the vaccination rate for a
susceptible individual and µ the natural mortality rate; σ represents the progress rate of zoster (activation)
in a vaccinated individual and δ the rate of reactivation of zoster by age in an asymptomatic individual.
Finally, both varicella and zoster infectious individuals recover with rate constants γ and  respectively.
We define β1 = kβ, with 0 ≤ k ≤ 1, as the transmission coefficient of the disease after vaccination.
The parameter k illustrates the effect of immunological memory. Thus it is the factor that reduces the
risk of varicella infection. In the case k = 0, the vaccine is effective and the immunological memory
developed against varicella infection does not wane over time; whereas k = 1 implies that the vaccine
is totally useless to induce immunological memory. From now on we make the realistic assumption that
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Figure 1. The flow diagram for the model (2.1). Individuals are classified as susceptible
(S), infectious (I), vaccinated (V ), asymptomatics, (A) and zoster (Z).
vaccination elicit immune response, but fails to offer long-lasting protection against varicella infection,
i.e. 0 < k < 1.
In the model described by Brisson et al. [3] individuals who had been immunised against varicella were
not able to develop zoster. Although zoster from the vaccine-type virus is very unlikely, it can occur, so
that a small fraction of those in the vaccinated class (V ) could get vaccine type zoster and move into the
zoster class (Z). In our model this possibility is allowed for, as studies suggest that vaccinated individuals
can, in fact, develop herpes-zoster [12].
Finally it is important to remark that a zoster individual is an infectious who cannot transmit the
infection to other individuals by air. The transmission of VZV from people with zoster can occur, but is
much less likely than from people with primary varicella [13], [2], [5]. Therefore we assume that zoster
individuals are infected, but not infectious individuals, i.e., they are not able to propagate the infection.
We now describe in detail each equation of (2.1). Susceptibles individuals, first equation, are recruited
at rate Π, and leave the class either by acquiring the varicella infection following contact with varicella
infectious individuals, or by being vaccinated, or by dying.
Taking into account that the interval between the first- and the second-dose varicella vaccination may
be short [18], and in any case the average intervaccination time of two months is short compared to the
lifetime of an individual, here we could simply assume the one-dose varicella vaccination schedule. In
other words, the one or possibly two doses vaccination will eventually lead to immunization, and the
parameter ρ will denote the rate at which the latter is obtained, no matter how in fact the vaccine is
administered.
Further, in the second equation we assume that susceptible individuals become varicella infectious
individuals via a successful contact between an infectious with a susceptible at rate β, or a vaccinated
one, at lower rate β1, when the vaccine protection wanes. The varicella-infectious individuals also leave
this class by being healed and therefore by migrating into the class of asymptomatics, i.e. those who have
been exposed to the virus and will carry it for life, although the latter may or may not be reactivated.
This class is also subject to natural mortality.
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Table 1. Description of variables and parameters for model (2.1)
Variables Description
S susceptible individuals
I varicella-infectious individuals
V vaccinated individuals
A asymptomatic individuals
Z zoster individulas
Parameters Description
Π susceptibles recruitment rate
β transmission coefficient of the susceptible individuals
β1 transmission coefficient of the vaccineted individuals
ρ vaccination rate for susceptible individuals
µ natural mortality rate
σ progress rate of zoster - activation
(yearly rate of vaccine-type zoster in vaccinated individuals)
δ reactivation rate of zoster by age in an asymptomatic individuals
(yearly rate of zoster per 100 000 people)
γ recovery rate from varicella infection
 recovery rate from zoster infection
The equation for vaccinated shows that these individuals are recruited at rate ρ from the class of
susceptibles, and can migrate into the class of infectious. This can happen in two circumstances. Firstly,
if the vaccine protection wanes, at rate β1. Secondly, assuming that zoster from the vaccine-type virus
can occur, here we can also assume that the vaccinated individuals move to the zoster class at rate σ.
Finally, vaccinated individuals are also subject to natural mortality.
Next, the asymptomatics dynamics is described in the fourth equation. They are coming either from
the infectious at the disease-recovery rate γ or from the zoster individuals at rate , first two terms, and
can leave after virus reactivation, due to a decrease of the immunitary defense system, to become zoster
at rate δ, or else via natural mortality, these outcomes being modeled by the last two terms.
Lastly, the zoster individuals enter the class either from the asymptomatic or the vaccinated classes,
at respective rates δ and σ and leave it by recovery to the class of asymptomatics at rate , or by dying.
Finally, since the physical situation being modelled concerns human populations, all the dependent
variables and parameters of the model are assumed to be nonnegative.
3. Model analysis
From the second equation (2.1) we find
I · (βS + β1V − (γ + µ)) = 0.
from which two types of equilibria are seen to exist, the chickepox-free one, in which I = 0 and the one
in which both chickepox and zoster coexist, I 6= 0.
We analyze each one of them separately. For stability purposes, we need also the Jacobian J ≡
J(S, I, V,A, Z) of (2.1), namely


−ρ− µ− βI −βS 0 0 0
βI βS + β1V − γ − µ β1I 0 0
ρ −β1V −β1I − σ − µ 0 0
0 γ 0 −δ − µ 
0 0 σ δ −− µ

 (3.1)
65
“mmnp˙Comba” — 2012/5/23 — 20:55 — page 66 — #5
i
i
i
i
i
i
i
i
M. Comba, S. Martorano-Raimundo, E. Venturino A vaccination model for varicella and zoste
3.1. Varicella-free equilibrium
The population levels of this equilibrium E1 = (S1, 0, V1, A1, Z1) are found to be
S1 =
Π
ρ+ µ
, (3.2)
V1 =
ρΠ
(ρ+ µ)(σ + µ)
,
A1 =
ρσΠ
µ(ρ+ µ)(σ + µ)(+ δ + µ)
,
Z1 =
Πρσ(δ + µ)
µ(ρ+ µ)(σ + µ)(+ δ + µ)
.
This equilibrium is always feasible, since all parameters are nonnegative.
We thus turn to its stability analysis. Substituting the components of E1 into (3.1) we find that with
I1 = 0 three eigenvalues of J(E1) are immediately obtained, namely: −(ρ+ µ), −(σ + µ) and
βS1 + β1V1 − (γ + µ) =
βΠ(σ + µ) + ρΠβ1 − (γ + µ)(ρ+ µ)(σ + µ)
(ρ+ µ)(σ + µ)
. (3.3)
The remaining ones are the roots of the quadratic equation,
λ2 + (δ + + 2µ)λ+ µ(δ + + µ) = 0.
which explicitly are found to be −µ, −(δ + + µ).
Hence, there is only one possibly nonnegative eigenvalue given by (3.3), on which stability depends.
In this way, the equilibrium point E1 is stable if only if the following condition holds,
βΠ(σ + µ+ kρ)− (γ + µ)(ρ+ µ)(σ + µ) < 0. (3.4)
Letting
βs =
(γ + µ)(ρ+ µ)(σ + µ)
Π(σ + µ+ kρ)
, (3.5)
we can rewrite (3.4) as
β
βs
< 1. (3.6)
One way to deal with this situation consists in introducing the concept of reproduction number in
presence of vaccine Rvacc, [7], so that the stability of the equilibrium point E1 holds for
Rvacc =
β
βs
< 1. (3.7)
We can also calculate the basic reproduction number. Setting ρ = 0 into (2.1), E1 simplifies to
S1|ρ=0 =
Π
µ
, I1|ρ=0 = 0, V1|ρ=0 = 0, A1|ρ=0 = 0, Z1|ρ=0 = 0,
and the simplified eigenvalues are the double one −µ and
βΠ − µ(γ + µ)
µ
, −(σ + µ), −(δ + + µ).
Letting
βL =
µ(γ + µ)
Π
(3.8)
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stability is then regulated by the inequality β < βL, or
R0 < 1, (3.9)
having defined the basic reproduction number as
R0 =
β
βL
. (3.10)
Further, Rvacc can now be rewritten in terms of R0 as follows
Rvacc = R0
µ(kρ+ σ + µ)
(ρ+ µ)(σ + µ)
(3.11)
from which R0 > Rvacc follows, since
µ(kρ+ σ + µ)
(ρ+ µ)(σ + µ)
< 1
is equivalent to
kµρ < ρσ + ρµ
from which dividing by ρ we get kµ < σ + µ i.e.
σ + µ · (1− k) > 0,
which is verified since 0 ≤ k ≤ 1.
The stability analysis can also be recast into other forms. In terms of ρ, starting from (3.4) by rewriting
it we find
ρ >
βΠ(σ + µ)− µ(γ + µ)(σ + µ)
(γ + µ)(σ + µ)− kΠβ
. (3.12)
If the right hand side is negative, evidently any positive amount of vaccination will be enough to stabilize
the equilibrium so that varicella is eradicated. The right hand side is positive if one of the two conditions
hold:
µ(γ + µ)
Π
< β <
(γ + µ)(σ + µ)
kΠ
;
µ(γ + µ)
Π
> β >
(γ + µ)(σ + µ)
kΠ
. (3.13)
If either one of (3.13) holds, then to eradicate the disease one needs a rate of vaccination which exceeds
the following value
ρs =
βΠ(σ + µ)− µ(γ + µ)(σ + µ)
(γ + µ)(σ + µ)− kΠβ
. (3.14)
Further, note that (3.4) can also be recast in the following form
ρ[
(γ + µ)(σ + µ)
µ(γ + µ)
−
kΠβ
µ(γ + µ)
] >
βΠ(σ + µ)
µ(γ + µ)
−
µ(γ + µ)(σ + µ)
µ(γ + µ)
,
from which, recalling (3.10) and (3.8), we have
ρ >
µ(σ + µ)(R0 − 1)
(σ + µ)− kµR0
.
Again if the right had side is negative, any positive vaccination rate ensures the eradication of the disease,
here. On the other hand, the right hand side is positive for one of the alternative conditions
1 < R0 <
σ + µ
kµ
; 1 > R0 >
σ + µ
kµ
. (3.15)
These once again ensure that ρs ≥ 0, where this threshold quantity can also be written as
ρs =
µ(σ + µ)(R0 − 1)
(σ + µ)− kµR0
(3.16)
and the varicella-free equilibrium is attained if the vaccination rate exceeds ρs.
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3.2. Coexistence Equilibrium
Solving the nonlinear system (2.1), for I 6= 0, we find the following population values for the coexistence
equilibrium E2 = (S2, I2, V2, A2, Z2)
S2 =
Π
βI2 + ρ+ µ
, (3.17)
V2 =
ρΠ
(βI2 + ρ+ µ)(β1I2 + σ + µ)
,
A2 =
δγI2(+ µ)(βI2 + ρ+ µ)(β1I2 + σ + µ) + ρσΠ
µ(βI2 + ρ+ µ)(β1I2 + σ + µ)(δ + + µ)
,
Z2 =
δγI2(βI2 + ρ+ µ)(β1I2 + σ + µ) + ρσΠ(δ + µ)
µ(βI2 + ρ+ µ)(β1I2 + σ + µ)(δ + + µ)
,
where the value of I2 is determined by the roots of the following quadratic
aI2 + bI + c = 0, (3.18)
a = kβ2(γ + µ) > 0,
b = (γ + µ)[kβ(ρ+ µ) + β(σ + µ)]− kβ2Π,
c = (γ + µ)(ρ+ µ)(σ + µ)−Π[kβρ+ β(σ + µ))].
All populations in (3.17) are nonnegative, so feasibility is obtained by discussing the sign of the roots
of (3.18). Descartes’ rule ensures one positive solution for c < 0, independently of the sign of b, and two
positive ones for b < 0 and c > 0. Now, b > 0 is equivalent to
β <
(γ + µ)(k(ρ+ µ) + σ + µ)
kΠ
≡ βb (3.19)
and c > 0 can be rewritten as
β <
(γ + µ)(ρ+ µ)(σ + µ)
Π(kρ+ σ + µ)
≡ βc. (3.20)
It is easily verified that βb > βc. Therefore for β < βc there are only negative roots, while for β > βc
there is one positive root. Now βc recalls the feasibility condition for the varicella-free equilibrium (3.5),
(3.6). The feasibility condition for the coexistence equilibrium is then
β >
(γ + µ)(ρ+ µ)(σ + µ)
Π(kρ+ σ + µ)
, (3.21)
recalling again (3.5), so that it can be rewritten as β > βs, from which finally
1 <
β
βs
≡ Rvacc.
This result is the opposite of the stability condition for the varicella-free equilibrium (3.9). When the
disease-free equilibrium is stable, the coexistence one is not feasible. Vice versa, when there is coexistence,
the disease-free equilibrium must be unstable. Further, for I2 = 0, the coexistence equilibrium becomes
the varicella-free one, compare their respective components (3.18) and (3.2). Thus mathematically we
have here a transcritical bifurcation: at Rvacc = 1 equilibrium E1 concides with E2 and when Rvacc grows
larger, the former loses its stability in favor of the latter.
Note that the coefficient of the polynomial (3.18) can be rewritten as
c = (γ + µ)(ρ+ µ)(σ + µ)(1−Rvacc). (3.22)
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Therefore, for Rvacc > 1, c < 0, there is only one positive root for the quadratic (3.18), i.e., the coexistence
equilibrium is feasible and must be stable. For Rvacc < 1, c > 0, there are two negative solutions for the
polynomial (3.18), i.e. only the varicella-free equilibrium exists and it is stable.
We now elaborate this result in terms of the vaccination rate ρ as done in the previous case. Expressing
(3.21) in terms of ρ we find
ρ <
µ(γ + µ)(σ + µ)− βΠ(σ + µ)
kβΠ − (γ + µ)(σ + µ)
≡ ρs. (3.23)
If the right hand side of (3.23) is negative then (3.21) does not hold, and the coexistence equilibrium is
then infeasible. For (3.21) to hold, we need a positive right hand side of (3.23), which is ensured by
ρ <
µ(σ + µ)(R0 − 1)
(σ + µ)− kµR0
.
In order that this inequality be satisfied, the right hand side must be positive. Then we obtain that the
conditions for which the coexistence equilibrium is feasible coincide with the stability conditions (3.15)
for the chickepox-free equilibrium earlier found.
The stability analysis of the interior coexistence equilibrium hinges on the full Jacobian (3.1). Luckily
the characteristic equation of this matrix factors, to give the following two explicit eigenvalues as roots
of a quadratic,
λ1 = −µ, λ2 = −(δ + + µ), (3.24)
which are both negative and therefore do not influence the stability issue. The remaining ones the are
roots of the monic cubic
λ3 + a2λ
2 + a1λ+ a0 = 0 (3.25)
with
a2 = (β − β1)I2 + βS2 + β1V2 + ρ− γ − µ− σ,
a1 = (−ρ− µ− βI2)(βS2 + β1V2 − β1I2 − γ − σ − 2µ) +
(βS2 + β1V2 − γ − µ)(−β1I2 − σ − µ)− β
2
1I2V2,
a0 = (ρ+ µ+ βI2)
[
(βS2 + β1V2 − γ − µ)(−β1I2 − σ − µ)− β
2
1I2V2
]
+
βS2(ββ1I
2
2 + β1ρI2).
To study stability using the Routh-Hurwitz conditions, since the signs of all coefficients are not easily
determined, is quite involved. Therefore we will investigate the stability only via numerical methods.
4. Simulations
The first results show that coexistence can indeed been achieved, as the theoretical analysis of the stability
of this equilibrium is missing, Figure 2.
Only for simulations purposes, we have chosen the fixed parameters as follows. We select k = 0.02
assuming the vaccine to be 98% effective; ρ = 0.85 assuming to be able to vaccinate 85% of the sus-
ceptibles; γ = 52.142 years−1, by converting into the time unit, the year, the disease infectious period,
which is 7 days; δ and σ are the rates at which zoster can appear, respectively after varicella and after
the vaccine administration; these parameters are estimated to be 70 and 17 persons every 100.000 per
year;  = 18.25 years−1 represents the reciprocal of the healing time, which is assumed to be 20 days;
µ = 1/85 years−1 is the reciprocal of life expectancy; assuming the average lifetime to be 85 years; the
immigration rate is taken Π = 100.000 people years−1, since the rate of progress of zoster is expressed
in terms of this population unit.
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From these values, we find
βs =
(γ + µ)(ρ+ µ)(σ + µ)
Π(kρ+ σ + µ)
= 9.27133 · 10−5.
and thus we take values of β just above and below βs, namely β = 9·10
−4 people−1 year−1 and β = 9·10−5
people−1 year−1.
In Figure 2, for β > βs, the system settles to the coexistence equilibrium E2 and for β < βs, the system
settles to the varicella-free equilibrium E1. These equilibria are explicitly given by
E1 = (116041, 0, 8264536, 119341, 82), E2 = (23829, 3705, 257599, 8214548, 317),
when β < βs.
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Figure 2. Profiles of populations for infectious individuals where (a) β > βs: coexistence
equilibrium; (b) β < βs: varicella-free equilibrium. System’s behavior for (a) β = 9 ·10
−4
and (b) β = 9 · 10−5.
4.1. System’s behavior as as function of β
We now perform further numerical experiments to investigate the behavior of the coexistence equilib-
rium when the parameters change. First we used as bifurcation parameter β. In a second phase, we
included also the vaccination rate ρ. Finally, together with these two parameters, also the influence of
the immmigration rate Π has been considered.
In Figure 3 we have the bifurcation diagram of I as a function of the disease incidence β. There is a
transcritical bifurcation (forward bifurcation) at β = βs = 9.27133 · 10
−5, (3.5) or Rvacc = 1. At that
point E1 becomes unstable, while E2 instead becomes feasible and stable. The transcritical bifurcation
affects also the other populations. A forward bifurcation occurs, that is, for Rvacc < 1, the varicella-free
equilibrium is locally asymptotically stable, and for Rvacc > 1, the coexistence equilibrium is locally
asymptotically stable. The diagram of the forward bifurcation corresponding to equation (3.18) as a
function of Rvacc is depicted in Figure 2.
The equilibrium change entails lower population values in the classes of susceptibles and vaccinated,
while the populations of asymptomatic individuals and of zoster increase as the infected do. The reason is
that S decreases for larger values of infected, since they become varicella infectious individuals. Therefore
also the number of susceptibles that can be vaccinated decreases. A larger value of I entails that more
asymptomatics and thus also more zoster individuals will appear in the population.
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Figure 3. Bifurcation diagram of I as function of β
4.2. System’s behavior as as function of β and ρ
We now investigate the modifications in the equilibria when both disease incidence and vaccination rate
change. In this case we therefore give a bifurcation diagram of I as function of β and ρ, Figure 4.
Figure 4. Bifurcation diagram of I as function of β and 0 ≤ ρ ≤ 1
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Note that the curve intersection of the surface with the β− ρ plane gives the locus of all the threshold
points βs, (3.5) which vary between the extreme values given by
βs|ρ=0 = 3.06861 · 10
−6, βs|ρ=1 = 9.86255 · 10
−5 (4.1)
In fact from (3.5) we have that βs ≡ βs(ρ), and Figure 4 depicts graphically this dependence.
4.3. Threshold behavior in terms of ρ and Π
Here we consider the threshold βs behavior in terms of the vaccination rate ρ and the immigration rate
Π, namely βs = βs(ρ,Π), see once again (3.5). We take as domain of the parameter plane the cartesian
product of the intervals ρ ∈ [0, 1] and Π ∈ [0, 10000000].
In Figure 5 for large values of Π, say 107, the threshold βs tends the faster to zero, the larger ρ is
and conversely, when Π approaches 0 the threshold grows the faster very large, the closer to 1 is the
vaccination rate. The minimal value we have obtained in the simulations is βs = 3.06861 · 10
−8. Thus
the smaller the immigration rate, the smaller the chances are of eradicating the disease.
Figure 5. Plot of β as a function of ρ and Π
5. Cost estimates
Here we analyze the costs that are incurred for treatment and other issues like doctors’ bills, laboratory
tests, hospitalizations, workdays or schooldays lost and so on, see for instance [21]. The data used here
are the ones reported in [20].
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The cost function is obtained as sum of the individuals costs, ci for infected, cv for vaccinated and cz
for zoster individuals, over a suitable time span tf ,
C =
∫ tf
0
(ciI + cvV + czZ)dt.
In general this function depends not only on these quantities, but on the disease incidence and the
vaccination rate as well, so that
C = C(β, ρ, I(t), V (t), Z(t)),
which needs to be minimized. This task has been performed numerically, in view of the complexity of
the problem, to get some insight into it.
Using the parameters already appearing in the simulations, we simulate the cost as function of the
remaining parameters, in particular at first the disease incidence β, taking into account also [14,20].
5.1. Cost as a function of β
Let us assume the individual costs to be 306e, 100e and 200e respectively for infected, vaccinated and
zoster individuals. For a population of 500000 individuals, we obtain the value of the average individual
cost as
153 · 106 e
5 · 105
= 306 e.
After obtaining the coexistence equilibrium values, the costs of each subpopulation are evaluated,
CI(t) = ciI(t), CV (t) = cvV (t), CZ(t) = czZ(t) and then the total one C(t) = CI(t) + CV (t) + CZ(t).
Repeating the calculation for each value of β, we thus find the graph of Figure 6. On summing each
Figure 6. C as function of β and time.
instantaneous cost over time and repeatig for each value of β we obtain the total cost in time
CT ≡ CT (β) =
365∑
t=0
C(t)
73
“mmnp˙Comba” — 2012/5/23 — 20:55 — page 74 — #13
i
i
i
i
i
i
i
i
M. Comba, S. Martorano-Raimundo, E. Venturino A vaccination model for varicella and zoste
From this, the extremal values are found respectively for β = 1 and β = 0
Cmin = 4.47181595378536 · 10
8
e, Cmax = 2.40930560139391 · 10
11
e.
There is thus a higher cost with varicella and vaccination, instead of the one with high infectivity. This
can be explained by looking at how each subpopulation behaves in time.
Starting from β = 0 we find that the sum of each subpopulation is∑
I(t) = 1,
∑
V (t) = 2.409258812 · 109,
∑
Z(t) = 2.339296341 · 104.
The largest population is the one of vaccinated individuals, therefore this one will bear the largest weight
in the cost calculation, in spite of having its pro-capita cost smaller than the other subpopulations.
Infected remain constant at 1, since the disease does not spread. Zoster individuals come only from
vaccine failures. The costs for each class are
CI = 306, e, CV = 2.40925881241 · 10
11
e, CZ = 4.67859268124 · 10
6
e.
On summing we find CT = 2.40930560139391 · 10
11 e.
We now analyze the case β = 1. The sum in each class is now∑
I = 1.39936520 · 106,
∑
V = 105.497125,
∑
Z = 9.48264717 · 104.
Here the largest class is I, containing about 106 individuals, while formerly the peak was at 1011. For
the costs we have
CI = 4.282057513 · 10
8
e, CV = 1.054971 · 10
4
e, CZ = 1.896529435 · 10
7
e
from which the total cost CT = 4.471815954 · 10
8 e.
We then analyze two intermediate situations for β, respectively above and below the threshold βs =
3.06861 · 10−8, (3.5), considering the interval [0, 0.00001]. Repeating the simulation, we obtain Figure
7. The total cost is almost constant, apart from some peaks, at about the level 2.4086 · 1011, and the
maximum is obtained for β = 0. For values of β larger than βs, we consider the interval [0.0001, 1], Figure
Figure 7. Graph of CT as function of β with β ∈ [0, 0.00001]
8. The values obtained fall in the interval [4.46 · 108, 4.47 · 108]. Therefore a vaccination program which
aims at involving 85% of the population is cheaper if the disease incidence has a high value, and it is not
worth the case to implement it when β falls below the threshold βs.
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Figure 8. Graph of CT as function of β with β ∈ [0.0001, 1]
5.2. Cost as a function of β and ρ
We now vary both disease incidence and vaccination rate. The intervals in which these are allowed to
vary are
ρ ∈ [0, 1], β ∈ [0, 0.00001] ∪ [0.1, 1]
The maximum for β < βs is
Cmax = 2.41567255166791 · 10
11
e
and Figure 9 contains the graphical display of the results. It shows that cost increases with ρ indepen-
dently of β, with a maximum at (β, ρ) = (0.000001, 1). Thus for β < βs we are better off minimizing the
vaccination rate. For β > βs, excluding the trivial case of the origin, with no disease evolution in the
Figure 9. Plot of the total cost as a function of β and ρ, with β < βs
population, namely (β, ρ) = (0, 0) with a cost of 306e, the minimal cost is, see Figure 10,
Cmin = 4.471700787594944 · 10
8
e .
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In this case, as β decreases and ρ increases, the cost becomes higher, up to the peak Cmaxrel =
4.48398374297879 · 108e at (β, ρ) = (0.1, 1). As β grows, the total cost decreases with a minimum
Figure 10. Plot of the total cost as a function of β and ρ, with β > βs
at (β, ρ) = (1, 1). But in this case almost all values are between 4.4717 · 108 and 4.4723 · 108. For smaller
β and the same ρ the cost is higher.
In summary, a herd vaccination program would make sense if the disease incidence β is above the
threshold, or if Rvacc > 1. In these cases costs can be minimized. But the disadvantage is that the
disease will not be eradicated, it will remain at an endemic level. Conversely, it is possible to eradicate
varicella, but this can be obtained only at large costs. Perhaps the tradeoff choice consists of keeping
around the threshold value βs, since this entails high cost, but not a maximal one together with the
possibility of eradicating the disease.
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